The main goals of treating bleeding disorders are to decrease the frequency and severity of bleeds, prevent long-term complications such as joint deformities and improve patient quality of life. These goals can be achieved by ensuring sufficient factor levels in the blood.
CSL Behring: Committed to coagulation therapies
The information in this site is brought to you by CSL Behring, a CSL Company. As a company with a long history creating a stable supply of life-saving therapies, CSL Behring provides plasma-derived and recombinant products used in the treatment of individuals with bleeding disorders, as well as the treatment of cardiac surgery patients and burn victims.
In fact, coagulation therapy is one of the keystones of our broad range of global therapies. Our extensive portfolio features over a dozen coagulation products (listed in the table below) used for the treatment of hemophilia A, hemophilia B, von Willebrand disease (VWD) and other factor deficiencies.
Learn more about CSL Behring’s coagulation therapies
Last Updated:
5/28/2010 7:21 PM